Sign in or create an account to add this stock to your watchlist.
About Onconova Therapeutics (NASDAQ:ONTX)
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680
Debt
Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.81
Price-To-Earnings
Trailing P/E Ratio-0.14
Forward P/E Ratio-0.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$790,000.00
Price / Sales9.47
Cash FlowN/A
Price / CashN/A
Book Value($1.01) per share
Price / Book-0.37
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-1,826.64%
Return on EquityN/A
Return on Assets-216.65%
Miscellaneous
Employees25
Outstanding Shares20,240,000
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Shares of Onconova Therapeutics reverse split on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics Inc. (NASDAQ:ONTX) announced its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $0.56 million during the quarter, compared to analyst estimates of $0.48 million. View Onconova Therapeutics' Earnings History.
When is Onconova Therapeutics' next earnings date?
What price target have analysts set for ONTX?
3 brokerages have issued 1 year target prices for Onconova Therapeutics' stock. Their predictions range from $3.00 to $6.00. On average, they anticipate Onconova Therapeutics' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.
What are Wall Street analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
- 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (5/19/2018)
- 2. Maxim Group analysts commented, "Summary We discuss in more detail below the meaning of the Interim analysis and the path to approval, including timelines and costs. Can Onconova get there? There are hurdles (aren’t there for most microcap biotech companies?), but we believe they can eventually, based on the fundamental prospects of Rigosertib." (3/26/2018)
- 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)
Are investors shorting Onconova Therapeutics?
Onconova Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totalling 1,499,501 shares, an increase of 98.7% from the April 13th total of 754,539 shares. Based on an average daily volume of 778,671 shares, the days-to-cover ratio is currently 1.9 days. Currently, 2.1% of the company's stock are sold short.
Who are some of Onconova Therapeutics' key competitors?
Some companies that are related to Onconova Therapeutics include BELLUS Health (BLUSF), Aralez Pharmaceuticals (ARLZ), Lipocine (LPCN), Egalet (EGLT), Citius Pharmaceuticals (CTXR), X T L Biopharmaceuticals (XTLB), Nuvo Pharmaceuticals (NRIFF), EyeGate Pharma (EYEG), Tonix Pharmaceuticals (TNXP), Benitec Biopharma (BNTC), Jaguar Health (JAGX), Regenerx Biopharmaceuticals (RGRX), Diffusion Pharmaceuticals (DFFN), Agile Therapeutics (AGRX) and Innovus Pharmaceuticals (INNV).
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Dr. Ramesh Kumar, Co-Founder, CEO, Pres & Director (Age 62)
- Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
- Dr. Steven M. Fruchtman, Chief Medical Officer and Sr. VP of R&D (Age 67)
- Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
- Mr. Mark Patrick Guerin, CFO & Principal Accounting Officer (Age 49)
Has Onconova Therapeutics been receiving favorable news coverage?
News headlines about ONTX stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Onconova Therapeutics earned a news sentiment score of 0.09 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.60 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Onconova Therapeutics' major shareholders?
Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.97%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.
Which major investors are selling Onconova Therapeutics stock?
How do I buy shares of Onconova Therapeutics?
Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of ONTX stock can currently be purchased for approximately $0.3695.
How big of a company is Onconova Therapeutics?
Onconova Therapeutics has a market capitalization of $7.35 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.
How can I contact Onconova Therapeutics?
Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]
MarketBeat Community Rating for Onconova Therapeutics (ONTX)
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Onconova Therapeutics (NASDAQ:ONTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Onconova Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 1,117.86%. The high price target for ONTX is $6.00 and the low price target for ONTX is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.75 | 2.75 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.50 | $8.00 | $7.3333 | $7.3333 |
| Price Target Upside: | 1,117.86% upside | 751.06% upside | 326.36% upside | 283.94% upside |
Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History
Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Onconova Therapeutics (NASDAQ:ONTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.70%
Institutional Ownership Percentage: 35.02%
Onconova Therapeutics (NASDAQ ONTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/27/2018 | 683 Capital Management, Llc | Major Shareholder | Buy | 11,838,235 | $0.43 | $5,090,441.05 | |  |
| 2/8/2018 | 683 Capital Management, Llc | Major Shareholder | Buy | 200,000 | $1.04 | $208,000.00 | | |
| 4/26/2017 | E Premkumar Reddy | Director | Buy | 119,048 | $2.10 | $250,000.80 | 385,832 | |
| 4/26/2017 | Mark Patrick Guerin | CFO | Buy | 1,429 | $2.10 | $3,000.90 | 5,155 | |
| 4/26/2017 | Ramesh Kumar | Insider | Buy | 23,810 | $2.10 | $50,001.00 | | |
| 2/21/2014 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 143,480 | $8.47 | $1,215,275.60 | 4,518,275 | |
| 2/10/2014 | Ramesh Kumar | CEO | Sell | 33,543 | $15.07 | $505,493.01 | | |
| 2/3/2014 | Ramesh Kumar | CEO | Sell | 60,000 | $15.05 | $903,000.00 | | |
| 1/27/2014 | Michael Hoffman | Director | Buy | 57,295 | $11.92 | $682,956.40 | | |
| 11/22/2013 | Michael Hoffman | Director | Buy | 5,000 | $14.39 | $71,950.00 | | |
| 11/18/2013 | E Premkumar Reddy | Director | Buy | 5,000 | $12.10 | $60,500.00 | 1,278,718 | |
| 11/15/2013 | & Jane Hoffman 2013 De Michael | major shareholder | Buy | 19,700 | $11.99 | $236,203.00 | 4,307,500 | |
| 11/15/2013 | Henry Bienen | Director | Buy | 1,400 | $12.17 | $17,038.00 | 14,935 | |
| 11/15/2013 | Ramesh Kumar | CEO | Buy | 1,100 | $12.02 | $13,222.00 | | |
| 7/30/2013 | & Jane Hoffman 2013 De Michael | Major Shareholder | Buy | 1,000,000 | $15.00 | $15,000,000.00 | | |
| 7/30/2013 | Ramesh Kumar | CEO | Buy | 6,667 | $15.00 | $100,005.00 | | |
| 7/30/2013 | Thomas J Mckearn | Insider | Buy | 3,333 | $15.00 | $49,995.00 | | |
| 7/30/2013 | Viren Mehta | Director | Buy | 16,667 | $15.00 | $250,005.00 | | |
| 7/25/2013 | E Premkumar Reddy | Director | Buy | 1,000 | $22.72 | $22,720.00 | | |
(Data available from 1/1/2013 forward)
Onconova Therapeutics (NASDAQ ONTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Onconova Therapeutics (ONTX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 19 at 10:57 AM |
 | Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT
finance.yahoo.com - May 17 at 10:16 AM |
| Onconova Therapeutics (ONTX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - May 16 at 9:56 AM |
 | Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 3:53 PM |
| Onconova Therapeutics (ONTX) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 15 at 1:31 PM |
| Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018
finance.yahoo.com - May 15 at 10:47 AM |
| Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX)
finance.yahoo.com - May 15 at 10:47 AM |
| Onconova Therapeutics Inc. (ONTX) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 13 at 1:40 AM |
| Zacks Investment Research Downgrades Onconova Therapeutics (ONTX) to Hold
www.americanbankingnews.com - May 10 at 11:28 AM |
| Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 10:08 AM |
| Onconova Therapeutics (ONTX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:14 AM |
| Rounds Report: Nephros Rallied While The Eleven Train Continued To Head Further North
seekingalpha.com - May 3 at 9:59 AM |
| Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018
finance.yahoo.com - May 3 at 9:59 AM |
| Onconova Therapeutics (ONTX) Raised to Buy at ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM |
 | UPDATE: Maxim Group Upgrades Onconova Therapeutics (ONTX) to Buy
www.streetinsider.com - May 2 at 3:55 PM |
| Onconova Therapeutics (ONTX) Raised to "Buy" at Maxim Group
www.americanbankingnews.com - May 2 at 2:36 PM |
| Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer?
finance.yahoo.com - May 2 at 10:02 AM |
| Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering
finance.yahoo.com - May 2 at 10:02 AM |
| Onconova Therapeutics Inc. (ONTX) Major Shareholder 683 Capital Management, Llc Purchases 11,838,235 Shares
www.americanbankingnews.com - May 1 at 7:18 PM |
| Onconova prices stock offering; shares down 7% premarket
seekingalpha.com - April 27 at 10:47 AM |
| Onconova Therapeutics (ONTX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 9:22 AM |
 | BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research ...
www.reuters.com - April 20 at 10:16 AM |
| Onconova Therapeutics (ONTX) Reports Data on Dual Inhibitor of CDK4/6 Plus ARK5 at 2018 AACR Meetings
www.streetinsider.com - April 20 at 10:16 AM |
| Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - April 19 at 10:18 AM |
| Onconova Therapeutics (ONTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 9:05 AM |
| Onconova readies equity offering; shares down 4% premarket
seekingalpha.com - April 18 at 10:18 AM |
| Onconova Therapeutics (ONTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 18 at 10:04 AM |
| Onconova Therapeutics Inc. (ONTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 16 at 1:42 AM |
| Onconova Therapeutics Inc. (ONTX) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 14 at 1:41 AM |
| Onconova Therapeutics (ONTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM |
| Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT
finance.yahoo.com - April 1 at 10:16 AM |
| Onconova Therapeutics (ONTX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - March 26 at 1:24 PM |
| Onconova Therapeutics (ONTX) Given "Hold" Rating at Maxim Group
www.americanbankingnews.com - March 26 at 1:24 PM |
| Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium
finance.yahoo.com - March 26 at 10:57 AM |
| Onconova Therapeutics Inc (ONTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 22 at 1:36 AM |
 | Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 3:56 PM |
| Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - March 15 at 11:01 AM |
| Onconova Therapeutics (ONTX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM |
| Onconova Therapeutics (ONTX) versus Trius Therapeutics (TSRX) Financial Analysis
www.americanbankingnews.com - March 14 at 7:52 PM |
| Onconova Therapeutics (ONTX) Releases Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - March 9 at 4:27 PM |
| Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 4:03 PM |
| Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 4:03 PM |
| Onconova Therapeutics (ONTX) Earns Hold Rating from Maxim Group
www.americanbankingnews.com - March 9 at 1:51 PM |
| Onconova Therapeutics to Present at the 30th Annual Roth Conference in March - GlobeNewswire (press release)
globenewswire.com - March 6 at 3:50 PM |
| Onconova (ONTX) Announces License Agreement with Pint Pharma to Commercialize Rigosertib in Latin America
www.streetinsider.com - March 6 at 10:36 AM |
| Onconova Therapeutics to Present at the 30th Annual Roth Conference in March
finance.yahoo.com - March 6 at 10:36 AM |
| Onconova Announces Presentation of Mechanism of Action Studies ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 4:02 PM |
| Onconova (ONTX) Announces License Agreement with Pint Pharma ... - StreetInsider.com
www.streetinsider.com - March 5 at 4:02 PM |
| Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America
finance.yahoo.com - March 5 at 11:13 AM |
| Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $310,000.00
www.americanbankingnews.com - March 3 at 3:08 PM |
Onconova Therapeutics (NASDAQ:ONTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement
Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
